Biotech Values

[ghmm]

rfj,
Your prediction is looking pretty good, unfortunately I had purchased some before your post. I've added more. Judging by the timing of their call and when the IND was filed for 237 (hyperoxaluria / kidney stones) and the fact that we have not had a negative PR they should announce it being accepted and hopefully dosing patients soon!

I haven't been too thrilled with their lack of progress with 238 (growth hormone) and their business development (what good is it to tout crystallization of 70+ proteins and not have the ability to form strategic collaborations). I'd think Biomarin would love to get their hands on 236 (PKU). I keep hoping Sidney wants to retire (he sure is selling his shares as quick as he gets them) and they can convince Michael Astrue to give up the government job (Bush's term is ending soon anyway) and become CEO. Its interesting that David Pendergast is on the board.